BiotechTube
Laplace Interventional

Laplace Interventional

San Carlos, United States· Est.
laplaceint.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $5M

Overview

Laplace Interventional is an early-stage, pre-revenue medical device company focused on the significant unmet need in tricuspid regurgitation (TR). The company is developing a proprietary transcatheter valve replacement (TTVR) system designed for percutaneous delivery, which could offer a safer, less invasive alternative to high-risk surgery. Operating from Plymouth, MN, and founded in 2018, the company is in the pre-clinical or early clinical investigation stage. Its success hinges on demonstrating the safety and efficacy of its novel device in a complex anatomical and competitive landscape.

Cardiovascular

Technology Platform

Transcatheter tricuspid valve replacement (TTVR) system for percutaneous, minimally invasive delivery of a prosthetic valve.

Funding History

1
Total raised:$5M
Seed$5M

Opportunities

The company addresses a massive untreated patient population with severe tricuspid regurgitation, representing a multi-billion dollar market opportunity.
Successful development could position Laplace as an attractive acquisition target for larger medtech companies seeking to enter or expand in the transcatheter tricuspid space.

Risk Factors

Laplace faces intense competition from well-funded rivals with more advanced clinical programs, and the complex tricuspid anatomy presents major technological and clinical trial risks.
As a pre-revenue company, it is also highly dependent on securing sufficient capital to fund expensive development through to potential regulatory approval.

Competitive Landscape

The transcatheter tricuspid intervention field is highly competitive, dominated by large players like Edwards Lifesciences (Evoque), Abbott (TriClip), and Medtronic, alongside several private companies. Many competitors have CE Mark approval and are conducting or have completed pivotal U.S. trials, giving them a significant head start over Laplace's investigational program.

More companies in Drug Delivery & Formulation →More companies in United States →